NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
3.880
+0.030 (0.78%)
At close: Apr 28, 2026, 4:00 PM EDT
3.927
+0.047 (1.21%)
After-hours: Apr 28, 2026, 4:10 PM EDT
NervGen Pharma Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 11.17 | 9.37 | 9.73 | 6.41 | 5.94 | |
| Research & Development | 13.91 | 15.81 | 8.05 | 16.61 | 6.87 | |
| Operating Expenses | 25.08 | 25.18 | 17.78 | 23.03 | 12.81 | |
| Operating Income | -25.08 | -25.18 | -17.78 | -23.03 | -12.81 | |
| Interest Expense | - | - | - | -0.51 | - | |
| Interest & Investment Income | 0.33 | 0.81 | 0.55 | 0.2 | 0.03 | |
| Currency Exchange Gain (Loss) | -0.41 | 0.25 | -0.16 | 0.71 | 0.06 | |
| Other Non Operating Income (Expenses) | -18.96 | -0.14 | -4.99 | 1.91 | - | |
| Pretax Income | -44.12 | -24.25 | -22.38 | -20.72 | -12.73 | |
| Net Income | -44.12 | -24.25 | -22.38 | -20.72 | -12.73 | |
| Net Income to Common | -44.12 | -24.25 | -22.38 | -20.72 | -12.73 | |
| Shares Outstanding (Basic) | 72 | 67 | 59 | 53 | 39 | |
| Shares Outstanding (Diluted) | 72 | 67 | 59 | 53 | 39 | |
| Shares Change (YoY) | 7.44% | 13.55% | 12.61% | 34.00% | 22.35% | |
| EPS (Basic) | -0.61 | -0.36 | -0.38 | -0.39 | -0.32 | |
| EPS (Diluted) | -0.61 | -0.36 | -0.38 | -0.39 | -0.32 | |
| Free Cash Flow | -19.5 | -16.84 | -11.3 | -17.81 | -8.27 | |
| Free Cash Flow Per Share | -0.27 | -0.25 | -0.19 | -0.34 | -0.21 | |
| EBITDA | -25.02 | -25.11 | -17.72 | -22.91 | -12.77 | |
| D&A For EBITDA | 0.06 | 0.06 | 0.06 | 0.12 | 0.04 | |
| EBIT | -25.08 | -25.18 | -17.78 | -23.03 | -12.81 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.